07:54 AM EDT, 03/21/2025 (MT Newswires) -- Senti Biosciences ( SNTI ) on Thursday filed a registration statement for the potential offering of about 52.9 million common shares by certain selling securityholders.

The company said it would not receive any proceeds from the potential sale. However, it added that it received around $47.6 million in proceeds from the issuances of the series A preferred stock and will receive proceeds from the exercise of the warrants, if exercised for cash.